United States securities and exchange commission logo October 14, 2020 Eric A. Adams President and Chief Executive Officer InMed Pharmaceuticals Inc. Suite 310-815 W. Hastings Street Vancouver, B.C. V6C 1B4 Canada Re: InMed Pharmaceuticals Inc. Amendment No. 4 to Registration Statement on Form S-1 Filed October 8, 2020 File No. 333-239319 Dear Mr. Adams: We have reviewed your amended registration statement and have the following comment. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to this comment, we may have additional comments. Amendment No. 4 to Registration Statement on Form S-1 filed October 8, 2020 Exhibits 1. Please have counsel file a revised Exhibit 5.1 opinion that includes the opinion that the warrants will be binding obligations of the company. For guidance, refer to Section II.B.1.f of Staff Legal Bulletin No. 19. Eric A. Adams FirstName LastNameEric A. Adams InMed Pharmaceuticals Inc. Comapany October 14,NameInMed 2020 Pharmaceuticals Inc. October Page 2 14, 2020 Page 2 FirstName LastName You may contact Ibolya Ignat at 202-551-3636 or Terence O'Brien at 202-551-3355 if you have questions regarding comments on the financial statements and related matters. Please contact Jeffrey Gabor at 202-551-2544 or Christine Westbrook at 202-551-5019 with any other questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Daniel M. Miller, Esq.